Association of the HTR2C gene and antipsychotic induced weight gain: A meta-analysis

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 697-704

  De Luca, Vincenzo ^a,b,c   Mueller, Daniel J ^a   De Bartolomeis, Andrea ^b   Kennedy, James L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; HTR2C; Meta analysis; Pharmacogenetics; Weight gain

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; SEROTONIN 2C RECEPTOR;

ARTICLE; BODY MASS; CLINICAL TRIAL; DNA POLYMORPHISM; FEEDING BEHAVIOR; GENE; GENETIC ASSOCIATION; HTR2C GENE; HUMAN; KNOCKOUT MOUSE; META ANALYSIS; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CONTINENTAL POPULATION GROUPS; DATABASES, BIBLIOGRAPHIC; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2C; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 34548409611     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007547     Document Type: Article

References (34)

1. Ashby Jr. CR, Wang RY (1996). Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349-394.
2. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy J (2002a). 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360, 1790-1791.
3. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL (2001). Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry 62 (Suppl.) 23, 45-66.
4. Basile VS, Masellis M, Potkin SG, Kennedy JL (2002b). Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human Molecular Genetics 11, 2517-2530.
5. Blin O, Micallef J (2001). Antipsychotic-associated weight gain and clinical outcome parameters. Journal of Clinical Psychiatry 62 (Suppl. 7), 11-21.
6. Castensson A, Aberg K, McCarthy S, Saetre P, Andersson B, Jazin E (2005). Serotonin receptor 2C (HTR2C) and schizophrenia: examination of possible medication and genetic influences on expression levels. American Journal of Medical Genetics. B: Neuropsychiatric Genetics 134, 84-89.
7. Castensson A, Emilsson L, Sundberg R, Jazin E (2003). Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biological Psychiatry 54, 1212-1221.
8. Collier DA (2003). Pharmacogenetics in psychosis. Drug News Perspectives 16, 159-165.
9. Correll CU, Malhotra AK (2004). Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berlin) 174, 477-489.
10. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-188.
11. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634.
12. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D (2005). Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 134B, 76-78.
13. Haddad PM (2004). Antipsychotics and diabetes: review of non-prospective data. British Journal of Psychiatry (Suppl.) 47, S80-86.
14. Harvey PD, Bowie CR (2005). Ziprasidone: efficacy, tolerability, emerging data on wide-ranging effectiveness. Expert Opinion in Pharmacotherapy 6, 337-346.
15. Henderson DC (2005). Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry 66 (Suppl. 6), 11-20.
16. Hong CJ, Lin CH, Yu YW, Yang KH, Tsai SJ (2001). Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 11, 265-268.
17. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, et al. (2005). Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. International Journal of Neuropsychopharmacology 8, 411-425.
18. Levitan RD, Masellis M, Basile VS, Lam RW, Kaplan AS, Davis C, Muglia P, Mackenzie B, Tharmalingam S, Kennedy SH, et al. (2004). The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biological Psychiatry 56, 665-669.
19. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S (2005). Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 133B, 97-100.
20. 2C receptor gene. APA Meeting 2003, San Francisco, USA.
21. Müller DJ, Muglia P, Fortune T, Kennedy JL (2004). Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research 49, 309-329.
22. Naylor CD (1997). Meta-analysis and the meta-epidemiology of clinical research. British Medical Journal 315, 617-619.
23. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl. 1), 1-93.
24. Reynolds GP, Templeman LA, Zhang ZJ (2005). The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 1021-1028.
25. Reynolds GP, Zhang Z, Zhang X (2003). Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. American Journal of Psychiatry 160, 677-679.
26. Reynolds GP, Zhang ZJ, Zhang XB (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359, 2086-2087.
27. Templeman LA, Reynolds GP, Arranz B, San L (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 15, 195-200.
28. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC, Remschmidt H, Hebebrand J (2004). Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatric Genetics 14, 139-142.
29. Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG, Ioannidis JP (2004). Establishment of genetic associations for complex diseases is independent of early study findings. European Journal of Human Genetics 12, 762-769.
30. Tsai SJ, Hong CJ, Yu YW, Lin CH (2002). -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360, 1790.
31. Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT, Kennett GA (2003). Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (Berlin) 167, 274-80.
32. Wetterling T (2001). Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety 24, 59-73.
33. Wilffert B, Zaal R, Brouwers JR (2005). Pharmacogenetics as a tool in the therapy of schizophrenia. Pharmacy World and Science 27, 20-30.
34. Yanovski JA, Yanovski SZ, Sovik KN, Nguyen TT, O'Neil PM, Sebring NG (2000). A prospective study of holiday weight gain. New England Journal of Medicine 342, 861-867.